Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
4.7
Journals
Biomedicines
Special Issues
Genetic and Epigenetic Mechanisms in Brain and Spinal Tumors
share announcement

Genetic and Epigenetic Mechanisms in Brain and Spinal Tumors

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular Genetics and Genetic Diseases".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1429

Special Issue Editors

Dr. Prit Benny Malgulwar

E-Mail Website
Guest Editor
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: CNS tumors; genetics; epigenomics; targeted therapy
Dr. Yogesh Srivastava

E-Mail Website
Guest Editor
Department of Genetics, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Interests: genetics; epigenomics; proteomics

Special Issue Information

Dear Colleagues,

This Special Issue, titled "Genetic and Epigenetic Mechanisms in Brain and Spinal Tumors", will mainly focus on understanding the role of genetic and epigenetic alterations as a driving force of oncogenesis and therapeutic resistance in brain and spinal neoplasms.

In recent years, genomic and molecular excavation has reported several genetic and epigenetic mechanisms, and has found itself to be critical in several aspects, including:

  • Tumor initiation: Genetic and epigenetic alterations can drive the initial transformation of normal cells into tumor cells by disrupting key regulatory pathways and promoting uncontrolled cell growth.
  • Tumor progression: These mechanisms can confer advantages to tumor cells, such as increased proliferative capacity, resistance to cell death, angiogenesis, invasion into surrounding tissues, and metastasis to distant sites.
  • Tumor heterogeneity: Genetic and epigenetic changes contribute to the development of heterogeneous tumor populations, leading to variations in cellular characteristics, therapeutic responses, and clinical outcomes.
  • Diagnostic and prognostic markers: Specific genetic and epigenetic alterations can serve as biomarkers for tumor classification, prognosis prediction, and treatment response assessment.
  • Therapeutic targets: Understanding the genetic and epigenetic landscape of brain and spinal tumors can help identify potential therapeutic targets and guide the development of targeted therapies aimed at specific molecular alterations.

By investigating the genetic and epigenetic mechanisms involved in brain and spinal tumors, this Special Issue aims to gain insights into the underlying biology of brain and spinal tumors, discover new diagnostic and prognostic markers, develop more effective treatments, and ultimately improve patient outcomes. Potential topics include, but are not limited to:

  • Recent advances in genomics and epigenomics biomarkers;
  • Novel therapeutic drugs based on genetic and epigenetic subtypes;
  • Novel tools for patient diagnosis and prognostication;
  • Cell signaling pathways based on genetic and epigenetic alterations.

Dr. Prit Benny Malgulwar
Dr. Yogesh Srivastava
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • CNS tumors
  • genetics
  • epigenomics
  • proteomics
  • drug modeling

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 11827 KiB  
Article
Association between the Use of Statins and Brain Tumors
by Sarang Jang, Hyo Gun Choi, Mi Jung Kwon, Ji Hee Kim, Joo-Hee Kim and So Young Kim
Biomedicines 2023, 11(8), 2247; https://doi.org/10.3390/biomedicines11082247 - 10 Aug 2023
Viewed by 1171
Abstract
This study aimed to investigate the effects of statin use on the incidence of brain tumors. The Korean National Health Insurance Service—National Sample Cohort from 2005 to 2019 was used. The 1893 patients who were diagnosed with brain tumors were matched with 7572 [...] Read more.
This study aimed to investigate the effects of statin use on the incidence of brain tumors. The Korean National Health Insurance Service—National Sample Cohort from 2005 to 2019 was used. The 1893 patients who were diagnosed with brain tumors were matched with 7572 control patients for demographic variables. The history of dyslipidemia was collected, and their history of prescription of statins before diagnosis of brain tumor was examined. The participants without dyslipidemia were set as a reference population. Then, the odds for brain tumors were analyzed in dyslipidemia patients without statin use, dyslipidemia patients who were prescribed statins for less than 365 days, and dyslipidemia patients who were prescribed statins for 365 days or more. Propensity score overlap weighted multivariable logistic regression analysis was used and adjusted for demographics and comorbidities. Secondary analyses were conducted according to types of statins, malignancy of brain tumors, and histories of demographics or comorbidities. A total of 11.78% of brain tumor patients and 10.95% of control participants had histories of statin use for 365 days or more. Dyslipidemia patients with 365 days or more duration of statin use demonstrated 1.22 times higher odds for brain tumors than normal participants (95% confidence intervals [CI] = 1.06–1.14, p = 0.007). Dyslipidemia patients with less than 365 days of statin use had higher odds of brain tumors than other groups (odds ratio = 1.60, 95% CI = 1.36–1.87, p < 0.001). The higher odds for brain tumors in short-term statin users (<365 days) than in long-term statin users (≥365 days) were consistent in secondary analyses according to types of statins, malignancy of brain tumors, and histories of demographics or comorbidities. Long-term statin use in dyslipidemia patients was related to a lower risk of brain tumors than short-term statin use in patients with dyslipidemia. Full article
(This article belongs to the Special Issue Genetic and Epigenetic Mechanisms in Brain and Spinal Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop